---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-017557"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:42:11.618763+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mira-55 shows morphine-comparable pain relief in animal model; SKNY acquisition clears SEC review

## Summary
- Mira-55, a non-psychoactive marijuana analog, matched morphine's pain relief in a formalin-based rodent model without sedation or inflammation.
- DEA previously confirmed Mira-55 is not a controlled substance, removing a key regulatory barrier to clinical development.
- SEC completed review of merger proxy for SKNY Pharmaceuticals acquisition with no comments, enabling shareholder vote.
- SKNY-1, the target therapy, demonstrated 30% body weight reduction without muscle loss and reversal of nicotine cravings in recent studies.
- MIRA advancing Mira-55 toward IND submission for inflammatory pain indications.

## SEC filing metadata
- accession: 0001641172-25-017557
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225017557/0001641172-25-017557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225017557/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-017557
- JSON: https://secwatch.observer/filing/0001641172-25-017557.json
- Plain text: https://secwatch.observer/filing/0001641172-25-017557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.